REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedPreclinical

Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides.

Filippenkov Ivan B, Glazova Nataliya Y, Sebentsova Elena A, Stavchansky Vasily V, Andreeva Lyudmila A, Myasoedov Nikolai F, Levitskaya Nataliya G, Limborska Svetlana A, Dergunova Lyudmila V
Biochemistry. Biokhimiia2024DOI: 10.1134/S0006297924090104
ACTH(4-7)PGP (Semax)ACTH(6-9)PGP

Quality Score

4/10

Citations

0

Subjects

Non-Human

PeptideVault Analysis

Study Design

Preclinical research is the foundation of the drug development pipeline. While these findings require human validation, they establish the mechanistic basis that informs dosing strategies, safety profiles, and target identification for future clinical work.

Our Assessment

Quality Assessment: 4/10 — This study contributes useful data but has methodological limitations that warrant caution. The findings are suggestive rather than definitive, and we'd recommend looking for corroborating evidence before drawing strong conclusions.

Findings in Context

These findings advance our understanding of ACTH(4-7)PGP (Semax), ACTH(6-9)PGP in meaningful ways.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Early-stage evidence for ACTH(4-7)PGP (Semax), ACTH(6-9)PGP. Interesting mechanistic insights, but we'll need human data before drawing practical conclusions.

Key Findings

The study identified differentially expressed genes in the rat brain frontal cortex following intraperitoneal administration of ACTH-like peptides, suggesting potential effects on gene expression that may be relevant to understanding their therapeutic mechanisms.

Limitations

The study is limited by its preclinical nature and use of rats, which may not fully translate to human clinical settings. Additionally, the specific physiological conditions under which these peptides are administered might limit generalizability.

Citation

Filippenkov Ivan B, Glazova Nataliya Y, Sebentsova Elena A et al.. (2024). Changes of Transcriptomic Activity in Rat Brain Cells under the Influence of Synthetic Adrenocorticotropic Hormone-Like Peptides.. Biochemistry. Biokhimiia. https://doi.org/10.1134/S0006297924090104

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.